Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: A twenty-four-week clinical trial

New approaches of B-cell-directed therapy: beyond rituximab

(2009) Thomas Dörner et al.   CURRENT OPINION IN RHEUMATOLOGY

Life threatening steroid-resistant autoimmune anemia successfully treated with rituximab: A case report

(2008) Nicolas Noel et al.   AMERICAN JOURNAL OF HEMATOLOGY

Spondylarthritis in the absence of B lymphocytes

(2008) Dominique Baeten et al.   ARTHRITIS AND RHEUMATISM

Successful treatment of refractory generalized myasthenia gravis with rituximab

(2008) C. Lebrun et al.   EUROPEAN JOURNAL OF NEUROLOGY

Lack of short-term efficacy of rituximab upon symptoms of ankylosing spondylitis treated for an associated vasculitis

(2008) Daniel Wendling et al.   JOINT BONE SPINE

Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases

(2008) Michael Hertl et al.   JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE

The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B

(2008) C. Rodriguez-Escalera et al.   RHEUMATOLOGY

Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production

(2008) R. J. Pepper et al.   RHEUMATOLOGY